NanoViricides, Inc., To Present At The Second Annual Marcum LLP MicroCap Conference

WEST HAVEN, Conn., May 29, 2013 /PRNewswire/ -- NanoViricides, Inc. (NNVC) announced today that Eugene Seymour, MD, MPH, Chief Executive Officer will present at the Second Annual Marcum LLP MicroCap Conference on Thursday, May 30, 2013 in New York City at the Grand Hyatt Hotel.

The Company's presentation is scheduled to begin at 1:30 p.m. EDT and will be available via a live webcast. To access the webcast, go to http://wsw.com/webcast/marcum/nnvc/.

For more information and registration, please visit the conference website: http://www.marcumllp.com/microcap

About NanoViricides, Inc.

NanoViricides, Inc. (www.nanoviricides.com) is a pre-clinical company that has created special purpose nanomaterials for use as antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company has developed several drug candidates against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, H7N9 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, rabies, dengue fever, and ebola virus, among others. An R&D facility that will incorporate a pilot cGMP manufacturing plant is currently under construction and will be leased by the Company when completed later this year. Material for upcoming human trials will be manufactured in this facility. Human trials will begin after completion of toxicology studies, commissioning of the manufacturing plant and submission of certain documents that require approval by regulatory authorities. The Company is funded through its initial human trials on its drug candidate, FluCide, for the eradication of various strains of influenza A.

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities.  Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in pre-clinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

About Marcum LLP

Marcum LLP is one of the largest independent public accounting and advisory services firms in the nation. Ranked among the top 15, Marcum LLP offers the resources of 1,000 professionals, including over 125 partners, in more than 20 offices throughout New York, New Jersey, Massachusetts, Connecticut, Pennsylvania, California, Florida, Grand Cayman and China. Headquartered in New York City, the Firm's presence runs deep with full-service offices strategically located in major business markets. Marcum is a member of the Marcum Group, an organization providing a comprehensive range of professional services spanning accounting and advisory, technology solutions, wealth management, and executive and professional recruiting. The Marcum Group companies include Marcum LLP; Marcum Technology LLC; Marcum Search LLC; Marcum Financial Services LLC; Marcum Bernstein & Pinchuk LLP; MarcumBuchanan Associates LLC; and Marcum Cronus Partners LLC.

Investor or Corporate Contacts:
TBTPR.com
Amanda Schuon
310-550-7200
info@nanoviricides.com

 

SOURCE Marcum LLP



RELATED LINKS
http://www.marcumgroup.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.